Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis

被引：0
|
作者：
Danese, S. [1 ]
Colombel, J-F [2 ]
Ponich, T. [9 ]
Jovanovic, I. [10 ]
Bossuyt, P. [11 ]
Longman, R. [3 ]
Alekseeva, O. [12 ]
Petersen, A. K. [4 ]
Marta, C. [4 ]
Charles, L. [4 ]
Sparrow, M. [13 ]
Rubin, D. T. [5 ]
Afzali, A. [6 ]
Loftus, E. V., Jr. [7 ]
Wolf, D. C. [8 ]
机构：
[1] IRCCS San Raffaele Hosp, Milan, Italy
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Weill Cornell Med, Jill Roberts Ctr Inflammatory Bowel Dis, New York, NY USA
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] Univ Chicago, Med Inflammatory Bowel Dis Ctr, Chicago, IL USA
[6] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA
[7] Mayo Clin, Div Gastroenterol & Hepatol, Coll Med, Rochester, MN USA
[8] Atlanta Gastroenterol Assoc, Ctr Crohns Dis & Ulcerat Colitis, Atlanta, GA USA
[9] Western Univ, London, ON, Canada
[10] Univ Hosp Med Ctr Bezanijska Kosa, Div Gastroenterol, Belgrade, Serbia
[11] Imelda Gen Hosp, Imelda GI Clin Res Ctr, Bonheiden, Belgium
[12] Nizhny Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia
[13] Monash Univ, Alfred Hosp, Melbourne, Vic, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2022年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
89
引用
收藏
页码：125 / 126
页数：2
相关论文
共 50 条
  • [41] CORTICOSTEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD: RESULTS FROM THE MAINTENANCE PHASE OF TRUE NORTH
    Schreiber, Stefan
    Armuzzi, Alessandro
    Dignass, Axel
    Marta, Cecilia
    Petersen, AnnKatrin
    Huang, Vivian
    Sandborn, William J.
    GASTROENTEROLOGY, 2021, 160 (06) : S83 - S83
  • [42] Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial
    Feagan, B. G.
    Sandborn, W. J.
    D'Haens, G.
    Hanauer, S.
    Wolf, D. C.
    Vermeire, S.
    Ghosh, S.
    Petersen, A.
    Hua, S. Y.
    Shan, K.
    Liu, J.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S464 - S464
  • [43] Matching-Adjusted Indirect Comparison of Etrasimod Versus Ozanimod for Clinical Response and Remission Among Patients With Moderately to Severely Active Ulcerative Colitis
    Jairath, Vipul
    Leahy, Thomas P.
    Potluri, Ravi
    Wosik, Karolina
    Gruben, David
    Cappelleri, Joseph C.
    Hur, Peter
    Bartolome, Lauren
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1058 - S1059
  • [44] INCIDENCE OF INFECTIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD AND RELATIONSHIP TO SIGNIFICANT LYMPHOPENIA: RESULTS FROM A POOLED SAFETY ANALYSIS
    Rieder, Florian
    Wolf, Douglas C.
    Charles, Lorna
    Kollengode, Kanthi
    Hsu, Kate
    Patel, Aditya
    Ghosh, Subrata
    GASTROENTEROLOGY, 2021, 160 (06) : S339 - S340
  • [45] Impact of risk factors for Janus kinase inhibitor use identified by the Pharmacovigilance Risk Assessment Committee on the safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis
    Siegmund, B.
    Kuehbacher, T.
    Armuzzi, A.
    Hart, A.
    Bressler, B.
    Feagan, B. G.
    Wu, H.
    Ahmad, H. A.
    Osterman, M. T.
    Charles, L.
    Poehler, A. M.
    Jain, A.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1461 - I1463
  • [46] EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
    Panaccione, Remo
    Afzali, Anita
    Hudesman, David
    Lawlor, Garrett
    Osterman, Mark T.
    Eren, Devrim
    Memaj, Arteid
    Regueiro, Miguel D.
    Ghosh, Subrata
    GASTROENTEROLOGY, 2022, 162 (07) : S965 - S965
  • [47] Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis
    Moein, Anita
    Lu, Tong
    Jonsson, Siv
    Ribbing, Jakob
    Kassir, Nastya
    Zhang, Wenhui
    Sperinde, Gizette
    Zhang, Rong
    Tang, Meina
    Oh, Young S.
    Bruno, Rene
    Zhu, Rui
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (09): : 1244 - 1255
  • [48] Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
    Garnock-Jones, K. P.
    BIODRUGS, 2015, 29 (01) : 57 - 67
  • [49] Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North
    Siegmund, B.
    Axelrad, J.
    Pondel, M.
    Osterman, M. T.
    Ahmad, H. A.
    Memaj, A.
    Regueiro, M.
    Armuzzi, A.
    Afzali, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I093 - I093
  • [50] RAPIDITY OF OZANIMOD-INDUCED SYMPTOMATIC RESPONSE AND REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE INDUCTION PERIOD OF TRUE NORTH
    Afzali, Anita
    Axelrad, Jordan E.
    Pondel, Marc
    Osterman, Mark T.
    Ahmad, Harris
    Memaj, Arteid
    Regueiro, Miguel D.
    Armuzzi, Alessandro
    Siegmund, Britta
    GASTROENTEROLOGY, 2022, 162 (07) : S976 - S976
12345